141 related articles for article (PubMed ID: 37913637)
1. PRAME expression in 137 primary cutaneous melanomas and comparison with 38 related metastases.
Lo Bello G; Pini GM; Giagnacovo M; Patriarca C
Pathol Res Pract; 2023 Nov; 251():154915. PubMed ID: 37913637
[TBL] [Abstract][Full Text] [Related]
2. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
3. PRAME expression in cutaneous melanoma does not correlate with disease-specific survival.
Parra O; Ma W; Li Z; Coffing BN; Linos K; LeBlanc RE; Momtahen S; Sriharan A; Cloutier JM; Wells WA; Yan S
J Cutan Pathol; 2023 Oct; 50(10):903-912. PubMed ID: 37430414
[TBL] [Abstract][Full Text] [Related]
4. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
5. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review.
Turner N; Ko CJ; McNiff JM; Galan A
Am J Dermatopathol; 2024 Jan; 46(1):21-30. PubMed ID: 37982498
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions.
Kunc M; Żemierowska N; Skowronek F; Biernat W
Histopathology; 2023 Jul; 83(1):3-14. PubMed ID: 36942814
[TBL] [Abstract][Full Text] [Related]
7. PRAME expression in melanocytic lesions of the nail.
Parra O; Linos K; Li Z; Yan S
J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
[TBL] [Abstract][Full Text] [Related]
8. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
9. Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas.
Toyama A; Siegel L; Nelson AC; Najmuddin M; Bu L; LaRue R; Henzler C; Caicedo-Granados E; Giubellino A; Li F
Mod Pathol; 2019 Dec; 32(12):1727-1733. PubMed ID: 31375769
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of combining PRAME and HMB-45 stains in primary melanocytic tumors.
Rasic D; Korsgaard N; Marcussen N; Precht Jensen EM
Ann Diagn Pathol; 2023 Dec; 67():152211. PubMed ID: 37717457
[TBL] [Abstract][Full Text] [Related]
11. PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics.
Chen YP; Zhang WW; Qiu YT; Ke LF; Chen H; Chen G
Histopathology; 2023 Jan; 82(2):285-295. PubMed ID: 36200756
[TBL] [Abstract][Full Text] [Related]
12. PRAME Expression Is a Useful Tool in the Diagnosis of Primary and Metastatic Dedifferentiated and Undifferentiated Melanoma.
Hornick JL; Plaza JA; Mentzel T; Gru AA; Brenn T
Am J Surg Pathol; 2023 Dec; 47(12):1390-1397. PubMed ID: 37727938
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics.
Rawson RV; Shteinman ER; Ansar S; Vergara IA; Thompson JF; Long GV; Scolyer RA; Wilmott JS
Pathology; 2022 Dec; 54(7):863-873. PubMed ID: 35987723
[TBL] [Abstract][Full Text] [Related]
14. PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.
Lezcano C; Jungbluth AA; Busam KJ
Surg Pathol Clin; 2021 Jun; 14(2):165-175. PubMed ID: 34023098
[TBL] [Abstract][Full Text] [Related]
15. Comparative Analysis of PRAME Expression in 127 Acral and Nail Melanocytic Lesions.
Santandrea G; Valli R; Zanetti E; Ragazzi M; Pampena R; Longo C; Lai M; Piana S; Cesinaro AM
Am J Surg Pathol; 2022 May; 46(5):579-590. PubMed ID: 35275883
[TBL] [Abstract][Full Text] [Related]
16. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
[TBL] [Abstract][Full Text] [Related]
17. PRAME immunohistochemistry is useful in differentiating oral melanomas from nevi and melanotic macules.
Schmitt TA; Lee JC; Martinka M; Ko KYC
J Cutan Pathol; 2023 Mar; 50(3):275-278. PubMed ID: 36398487
[TBL] [Abstract][Full Text] [Related]
18. PRAME expression in melanocytic lesions of the conjunctiva.
Šekoranja D; Hawlina G; Pižem J
Histopathology; 2021 Dec; 79(6):989-996. PubMed ID: 34268800
[TBL] [Abstract][Full Text] [Related]
19. PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation.
Kline N; Menge TD; Hrycaj SM; Andea AA; Patel RM; Harms PW; Chan MP; Bresler SC
Am J Dermatopathol; 2022 Jun; 44(6):404-410. PubMed ID: 34991102
[TBL] [Abstract][Full Text] [Related]
20. PRAME immunohistochemistry of spitzoid neoplasms.
Koh SS; Lau SK; Scapa JV; Cassarino DS
J Cutan Pathol; 2022 Aug; 49(8):709-716. PubMed ID: 35488519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
